EichorEICHOR
Location: Edmonton Synced from ClinicalTrials.gov · August 08, 2026

Clinical studies recruiting near Edmonton

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Prediction of Intraventricular Hemorrhage Using Echocardiography and Near Infrared Spectroscopy
Phase N/A · Royal Alexandra Hospital · Mount Sinai Hospital, Canada · NCT05708105Observational Study Protocol: LIVER-R
Phase N/A · Research Site · AstraZeneca · NCT06252753Transpulmonary Assessment for Individualized Lung Optimization in Obese Patients
Phase 2 · University of Alberta Hospital · University of Alberta · NCT07359261A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart
Phase 3 · CON-11011, Edmonton, AB · Colorado Prevention Center · NCT06024746Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
Phase 3 · University of Alberta Hospital · Joseph Broderick, MD · NCT07227246Clinical Investigation of MYIBDDiet App Developed for Inflammatory Bowel Disease (IBD) Patients to Self-manage Their Die
NA · Zeidler Ledcor Centre, University of Alberta · University of Alberta · NCT06683105Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease
Phase 2/Phase 3 · Local Institution - 0020 · Bristol-Myers Squibb · NCT07106762Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy
Phase 2 · Peter S. Allen MRI Unit · University of Alberta · NCT06483061Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · Cross Cancer Institute ( Site 0407) · Merck Sharp & Dohme LLC · NCT06393374MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · University of Alberta Hospital · National Cancer Institute (NCI) · NCT05564390A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) G
Phase 1/Phase 2 · University of Alberta Hospital · National Cancer Institute (NCI) · NCT05099003Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed
Phase 3 · University of Alberta Hospital · National Cancer Institute (NCI) · NCT06172296A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
Phase 3 · University of Alberta, Edmonton · Vertex Pharmaceuticals Incorporated · NCT04786262Carotid Intraplaque Neovascularization Combined With Stress Echo
Phase N/A · University of Alberta · Dr. Amer Johri · NCT0541638518F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028
Phase 3 · University of Alberta · University of Alberta · NCT05520255Telemonitoring of Hypertensive Patients With Chronic Kidney Disease
NA · University of Alberta · University of Alberta · NCT04098354STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Phase 3 · ADARx Clinical Site · ADARx Pharmaceuticals, Inc. · NCT06960213Breakthrough CMV Lung Transplant -Multicentre
Phase N/A · University of Alberta Hospital · University of Alberta · NCT04439916UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease
Phase N/A · Stollery Children's Hospital · The Hospital for Sick Children · NCT06560606A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au
Phase 3 · Local Institution - 0111 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · NCT07424404A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Phase 2 · University of Alberta Hospital · Children's Oncology Group · NCT06368817A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Phase 2/Phase 3 · University of Alberta Hospital · National Cancer Institute (NCI) · NCT05691478Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov
Phase 3 · Janek Senaratne Professional Medical Corporation · Amgen · NCT07037433Utilizing an EEG-Based BCI Game to Evaluate Cognitive Skills in Children With Motor Impairments
Phase N/A · University of Alberta · University of Alberta · NCT07109830Improving Health Outcomes With Kefir
NA · University of Alberta · University of Alberta · NCT06695221Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences
Phase 4 · University of Alberta · University of Alberta · NCT05997732Nutritional Supplementation in Head and Neck Cancers
Phase 2 · Cross Cancer Institute · AHS Cancer Control Alberta · NCT05379712A Platform Trial for Gram Negative Bloodstream Infections
NA · University of Alberta · Sunnybrook Health Sciences Centre · NCT06537609A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · Local Institution - 2202 · Turning Point Therapeutics, Inc. · NCT03093116A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child
Phase 3 · Stollery Children's Hospital | Cardiology · Bayer · NCT07192952
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.